Could melatonin prevent Vancomycin-induced nephrotoxicity in critically ill patients? A randomized, double-blinded controlled trial.

• DOI: 10.22088/cjim.14.1.76
• Publication Date: 2023-01-01
• Authors: Saeed Abbasi; Ehsan Bigharaz; Shadi Farsaei; Marjan Mansourian
• Keywords: Nephrotoxicity

Previous research showed some clinical benefits regarding the nephroprotective effect of melatonin. So, this study aimed to evaluate beneficial oral melatonin on preventing acute kidney injury (AKI) in patients who received vancomycin therapy intensive care unit (ICU).We performed a randomized, double-blinded, placebo-controlled pilot an academic hospital. Adult admitted ICU with normal gastrointestinal and function were randomized into treatment or placebo groups. After that, enrolled tablet (3 mg) twice daily for seven consecutive days. The occurrence AKI was assessed by RIFLE criteria (by measurement serum creatinine (SCr)) plasma neutrophil gelatinase-associated lipocalin (NGAL) concentration. Moreover, other data related renal functions SOFA also compared between groups.A total 90 included study, while 21patients group 20 intervention completed study. There no significant differences groups baseline SCr, BUN, urine output, NGAL, SOFA, glomerular filtration rate (GFR). Our results that these remained insignificant after 7-day follow-up However, incidence significantly lower based NGAL cutoff (> 150 ng/mL).We detected decrease vancomycin-induced nephrotoxicity receiving placebo. more trials larger population required confirm result.